Targeting oxidative stress through NRF2 activation represents a promising future strategy for discovering drugs to treat SCD, since this transcription factor plays a pivotal role in cellular defenses against oxidative stress through the enhanced transcription of antioxidant genes. This evidence concerns the gene NFE2L2 and Schnyder corneal dystrophy.